Core Viewpoint - The stock of Kintor Pharmaceutical (02171) has seen a significant increase, rising over 8% during trading, with a current price of HKD 17.52 and a trading volume of HKD 51.9354 million. This surge is linked to the ongoing negotiations for the 2025 National Medical Insurance pricing, which may positively impact CAR-T therapies, including Kintor's Zewokaiolun injection [1]. Group 1 - The negotiations for the 2025 National Medical Insurance are currently in their fourth day, with representatives from HeYuan Bio expressing that discussions have been smooth, although final results will depend on the National Healthcare Security Administration's announcement [1]. - There are currently seven CAR-T products approved in China, all priced over one million yuan, with five undergoing review through the commercial insurance directory, including Kintor's Zewokaiolun injection [1]. - Inclusion of CAR-T therapies in the commercial insurance directory is expected to enhance patient accessibility, reduce financial burdens, alleviate pricing pressure on pharmaceutical companies, expand market share, and ensure reasonable returns for high-value innovative therapies [1].
港股异动 | 科济药业-B(02171)盘中涨超8% CAR-T药物有望进入商保 泽沃基奥仑赛注射液此前通过初审